ERIS inhibitors represent a class of chemical compounds specifically designed to selectively interact with and inhibit the activity of the ERIS protein. These inhibitors work by binding to the active sites or allosteric sites of ERIS, which can impede the protein's natural function, typically involved in a range of cellular processes. The design of ERIS inhibitors is based on the molecular structure and the biological pathways in which ERIS operates, ensuring that these compounds are efficient in their inhibitory action. The binding of these inhibitors to ERIS leads to a conformational change in the protein or blocks the site where the natural substrate would bind, effectively preventing ERIS from participating in its normal cellular roles. The specificity of ERIS inhibitors is crucial as it ensures that the inhibition is limited to the ERIS protein and does not undesirably affect the function of other proteins.
The development of ERIS inhibitors is grounded in a comprehensive understanding of the protein's role in its specific signaling pathways. By targeting the intricate mechanisms that regulate ERIS activity, these inhibitors can disrupt the downstream effects that ERIS may have in various cellular pathways. The precision of these inhibitors is achieved through rigorous molecular engineering, which allows them to have a high affinity for ERIS while minimizing off-target interactions. Furthermore, the action of ERIS inhibitors is reversible, meaning that they do not irreversibly modify the protein, thus allowing for controlled inhibition. This reversible nature is beneficial for finely tuning the extent of ERIS activity in a temporal manner, providing a strategic advantage in scenarios where the modulation of ERIS activity is desired. These inhibitors are an example of the advances in chemical biology that enable the modulation of specific protein functions without altering the genetic or transcriptional landscape within the cell.
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
A specific inhibitor of mitogen-activated protein kinase kinase (MEK), which indirectly inhibits ERIS by preventing the activation of ERK downstream, a kinase that could phosphorylate and activate ERIS if ERIS is a phosphorylation substrate. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A potent inhibitor of PI3K, which blocks the PI3K/AKT pathway; if ERIS activity is linked to this pathway, its inhibitory effect on AKT activation can lead to reduced ERIS activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor that can impede the MAPK pathway; if ERIS is activated by p38 MAPK, inhibiting this kinase will decrease ERIS activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
A highly selective inhibitor of both MEK1 and MEK2, which can lead to reduced activation of ERK; if ERIS is downstream of ERK, U0126 would result in diminished ERIS activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that can block the mTORC1 pathway; if ERIS is activated by mTORC1 signaling, rapamycin would lead to decreased ERIS functional activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
A covalent inhibitor of PI3K that, by inhibiting the PI3K/AKT pathway, may reduce ERIS activity if ERIS is regulated by this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), which would lead to decreased ERIS activity if ERIS is modulated by the JNK signaling pathway. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
A receptor tyrosine kinase inhibitor that might affect ERIS activity indirectly by inhibiting upstream receptor autophosphorylation and subsequent signaling that may activate ERIS. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
An EGFR tyrosine kinase inhibitor that could decrease ERIS activity by inhibiting EGFR-mediated signaling pathways that could potentially be activating ERIS. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Similar to gefitinib, erlotinib is another EGFR inhibitor that can downregulate signaling pathways potentially leading to the activation of ERIS. |